Alimera Sciences Stock
Your prediction
Pros and Cons of Alimera Sciences in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
B****
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Alimera Sciences vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Alimera Sciences | - | - | - | - | - | - | - |
| Pacira Pharmaceuticals | 0.000% | -6.604% | -10.000% | -5.714% | -8.333% | -40.361% | -59.091% |
| Corcept Therapeutics Inc. | 2.030% | 3.278% | 26.554% | 61.350% | 44.691% | 248.380% | 443.626% |
| Supernus Pharmaceuticals | -0.480% | 11.230% | 0.483% | 16.201% | -3.256% | 43.448% | 100.000% |
Comments
Alimera Sciences, Inc. (NASDAQ: ALIM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Show more
Ratings data for ALIM provided by MarketBeat
Alimera Sciences, Inc. (NASDAQ: ALIM) is now covered by analysts at Maxim Group. They set a "buy" rating and a $10.00 price target on the stock.
Show more
Ratings data for ALIM provided by MarketBeat
Alimera Sciences, Inc. (NASDAQ: ALIM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Show more
Ratings data for ALIM provided by MarketBeat